Gregg L. Semenza, M.D., Ph.D.
C. Michael Armstrong Professor of Genetic Medicine, Pediatrics, Medicine, Oncology, Radiation Oncology, and Biological Chemistry;
Director, Vascular Program, Institute for Cell Engineering;
Johns Hopkins University School of Medicine
One of today's preeminent researchers on the molecular mechanisms of oxygen regulation, Dr. Semenza has led the field in uncovering how cells adapt to changing oxygen levels. He is best known for his ground-breaking discovery of the HIF-1 (hypoxia-inducible factor 1) protein, which controls genes in response to changes in oxygen availability. The finding has far-reaching implications in understanding and treating low-oxygen health conditions such as coronary artery disease and tumor growth.
Dr. Semenza was recognized for this groundbreaking research in 2019, when awarded the Nobel Prize in Physiology or Medicine by the Royal Swedish Academy of Sciences. He shares the award with William G. Kaelin, Jr., M.D. of the Dana-Farber Cancer Institute and Peter J. Ratcliffe of Oxford University.
He received his A.B. from Harvard University. He earned his M.D. and Ph.D. from the University of Pennsylvania, completed his residency in pediatrics at Duke University Medical Center and performed postdoctoral research in medical genetics at Johns Hopkins. Dr. Semenza joined the Johns Hopkins faculty in 1990.
Dr. Semenza's research interests include the molecular mechanisms of oxygen homeostasis; gene and stem cell therapy for ischemic cardiovascular disease; the role of HIF-1 in cancer; and protection of the heart against ischemia-reperfusion injury. He has authored more than 250 research articles and several book chapters, and has been cited in research more than 30,000 times.
He is a founding fellow of the American College of Medical Genetics and was elected to the Association of American Physicians and the National Academy of Sciences in 2008. He serves on the editorial board of several journals, including Molecular and Cellular Biology and Cancer Research, and is editor-in-chief of the Journal of Molecular Medicine.
Michael Forster, Ph.D., Chairman and Regents Professor,
University of North Texas Health Science Center (UNTHSC)
Fort Worth, Texas
Past President of the International Society on Aging and Disease
Past President of the American Aging Association
Dr. Forster is recognized internationally for research on the role of oxidative stress in age-associated brain dysfunction and in the anti-aging effects of caloric restriction. Dr. Forster is Director of the UNTHSC site for the National Institute on Drug Abuse- Addiction Treatment Discovery Program (ATDP), and has directed his program continuously with National Institute on Drug Abuse- Addiction Treatment Discovery Program (ATDP) for 20 years, evaluating and reporting on over 3,000 potential medications for the treatment of drug addition, using behavioral pharmacology methods of analysis. In addition, Dr. Forster developed and validated rodent models for assessment of age-related changes in brain function, and established outstanding testing facilities appropriate for assessing the effects of long-term interventions.
Dr Forster served on the editorial board of Experimental Biology and Medicine, Mechanisms of Ageing and Development, and Journal of the American Aging Association, has been the recipient of numerous local and national awards for academic excellence, and has been awarded the title of Regents Professor. He is currently immediate past President of The American Aging Association, an international organization dedicated to basic research in biogerontology.
James W. Simpkins, Ph.D., Professor,
Director, Center for Basic & Translational Stroke Research
West Virginia University
Past President of International Society on Aging and Disease.
James W. Simpkins received his Ph.D. degree under the mentorship of the pioneering neuroendocrinologist, Joseph Meites at Michigan State University in 1977. He then jointed the University of Florida when he rose through the academic ranks to a full professorship in 1986. At the University of Florida, he was the founding director of the Center for the Neurobiology of Aging, served as Chair of two departments and was appointed the Frank Duckworth Professor of Drug Discovery in 1996. In 2000, he became the Professor and Chair of the Department of Pharmacology & Neuroscience and Founding Director of the Institute for Aging and Alzheimer’s Disease Research at the University of North Texas Health Science Center at Fort Worth. In 2012, he joined the faculty of the Department of Physiology and Pharmacology of West Virginia University and serves as the Founding Director of the Center for Basic and Translational Stroke Research. In 2012, he received the Harman Award for Life-time Achievement for Aging Research from the American Association of Aging. In 2015, he was named the Highland Chair of Stroke/Neurology at the WVU. The author of 420 full length publications, his research has focus on the discovery of novel compounds for the treatment of age-related brain disorders, with a particular focus on Alzheimer’s disease and stroke. His body of research has resulted in 22 issued US and foreign patents. He has mentored numerous PhD students, post-doctoral fellows and junior faculty to research and career success at the University of Florida, the University of North Texas Health Science Center and continued to do so at the West Virginia University.
Antonio Cano, M.D.
Full professor of Obstetrics and Gynecology
President of the European Menopause and Andropause Society.
President of the Obstetrical and Gynecological Society of the Valencia Community.
Department of Pediatrics, Obstetrics and Gynecology, University of Valencia
Antonio Cano is full Professor of Obstetrics and Gynecology at the University of Valencia, Spain, and Head of the Service of this specialty at the Clinico University Hospital in Valencia. His main interest is Reproductive Endocrinology, and particularly hormonal phenomena linked with climacterium and aging. He was graduated by the University of Valencia, in 1978. His MD was obtained at the University of Bologna, Italy, where he was scholar in the Royal Spanish College, attached to that University. His clinical training started as a resident in Obstetrics and Gynecology at the Hospital de la Santa Cruz y San Pablo, in Barcelona, Spain and was subsequently completed at the University Hospital in Murcia, also in Spain. He spent two periods (1982 and 1984-1985) as a postdoctoral fellow in the Imperial Cancer Research Fund in London, UK, through grants from the British Council-Spanish Ministry of Education. His work focused on molecular details of steroid action, including some details of hsp proteins. Since then, he leads a group that works in some areas where hormonal action is involved in clinical problems, and particularly on aspects of ageing in women, such as cardiovascular disease, osteoporosis and frailty. He has authored several books and about two hundred and fifty articles written in English or Spanish. He is also a frequent speaker in national and international meetings, a member of the Board in three scientific journals, Maturitas, Gynecologic and Obstetric Investigation, and Pregnancy Hypertension, and editor for Gynecology of the European Journal of Obstetrics, Gynecology and Reproductive Biology.
Holly M. Brown-Borg, Ph.D.
Chester Fritz Distinguished Professor
Department of Pharmacology
Physiology and Therapeutics
University of North Dakota School of Medicine & Health Sciences
Holly is Past-President of the American Aging Association and current Biological Sciences Chair of the Gerontological Society of America. She is also Organizer of the International Symposia on Neurobiology and Neuroendocrinology of Aging, Bregenz, Austria.
A popular theory to explain the physiological decline that occurs during aging involves oxidative stress and subsequent damage to DNA, proteins, and lipids. Delaying this decline is associated with extended lifespan. Mice with hereditary dwarfism (Ames dwarf, df/df) and growth hormone (GH) deficiency exhibit delayed aging, living more than a year longer than normal siblings (P<0.0001), differences in antioxidant defense capacity, and lower DNA damage. In contrast, mice with high plasma GH concentrations live half as long as normal, wild type siblings and exhibit a depressed antioxidative defense capacity. The overall hypothesis is that the Ames dwarf mouse has a biologic advantage over normal wild type mice with better enzymatic scavenging of toxic metabolic byproducts and less mitochondrial membrane leakage underlying their enhanced longevity.
Holly’s current studies are designed to further understand the relationship between cellular oxidation, hormones, mitochondrial activities, and aging in a mammalian model of extended lifespan. Determining the pathways and mechanisms that GH utilizes may suggest potential therapeutic interventions that could lead to strategies to delay aging, treat aging-related disorders, and extend lifespan in humans.
Prof. Amanda Salis (nee Sainsbury)
Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders
Central Clinical School
Faculty of Medicine and Health
The University of Sydney
With a Bachelor of Science (with First Class Honours) from the University of Western Australia and a PhD from the University of Geneva, Switzerland, Professor Amanda Salis (nee Sainsbury) leads a research team at the University of Western Australia's School of Human Sciences that aims to help people to attain and maintain an optimum body weight and composition.
Her translational research into hypothalamic control of appetite, eating behavior, energy expenditure, body weight and body composition spans transgenic mice, adults with overweight or obesity (with or without eating disorders), as well as adult athletes.
Her randomized controlled trials comparing long-term effects of fast versus slow weight loss – using intermittent versus continuous energy restriction – are funded by a Senior Research Fellowship and Project Grants from the National Health and Medical Research Council (NHMRC) of Australia.
Dr. Alexey Moskalev
Head of the Laboratory of Molecular Radiobiology and Gerontology
Institute of Biology, Komi Science Center of RAS
Alexey Moskalev (born 5 November 1976) is an Professor of Russian Academy of Sciences, Doctor of Biology, the Head of the Laboratory of Molecular Radiobiology and Gerontology in the Institute of Biology of Komi Scientific Centre of the Ural Branch of the Russian Academy of Sciences, the Head of the Department of Ecology of the Syktyvkar State University named after Pitirim Sorokin, the Head of the Laboratory of Genetics of Aging and Longevity in the Moscow Institute of Physics and Technology.
A. Moskalev graduated from the Syktyvkar State University. He studied at the Department of Human and Animal Physiology of the Chemical-Biological Faculty. In 1996, he started working in the Department of Radioecology, Institute of Biology of the Ural Branch of the Russian Academy of Sciences. At present, he is the Head of the Laboratory of Molecular Radiobiology and Gerontology in the Institute mentioned as well as laboratory of Genetics of aging and longevity at Moscow Institute of Physics and Technology.
Department of Molecular Biology and Genetics
Gustav Wieds Vej 10
8000 Aarhus C
SURESH RATTAN, Ph.D.,D.Sc., is a biogerontologist at the Department of Molecular Biology and Genetics, Aarhus University, Denmark. His research areas and expertise include ageing of human cells and application of the concept of mild stress-induced hormesis as a modulator of ageing. He is the recipient of the Lord Cohen Medal in Gerontology from the British Society for Research on Ageing (BSRA), and an Honorary Doctorate from the Russian Academy of Medical Sciences. He has published more than 250 scientific articles, and has edited/co-edited 15 books, including books for children, general public and research scientists. He is the founder and Editor-in-Chief of Biogerontology – an international peer reviewed journal published by Springer-Nature. He is the present Chairman of the Biological Section of the European Region of the International Association of Gerontology and Geriatrics (IAGG-ER). His personal website is: www.sureshrattan.com
Marios Kyriazis, MD, MSc (Gerontology),
National Gerontology Centre
Marios Kyriazis is Biomedical Gerontologist & Anti-aging Physician at the British Longevity Society and is on the Editorial Board of Rejuvenation Research.
Marios received primary and secondary education in Larnaca (Cyprus), and after military service, he studied Medicine at the University of Perugia and then the University of Rome (Italy). In 1982, he received his medical degree and went on to train as a junior doctor in a variety of hospital posts in Cyprus, New York (USA), Sheffield and Northampton (UK). In 1987, he gained a Bachelor of Arts degree and then studied for a Master of Science degree in gerontology at King’s College London (1990). He was awarded a Diploma in Geriatric Medicine by the Royal College of Physicians in 1990, and subsequently became a Chartered Biologist, Member of the Institute of Biology (UK).
In 1992, Marios founded the British Longevity Society, a nonprofit organization aiming to provide research-based information on healthy aging to the general public. He wrote on the subject of free radicals and antioxidants, and his paper on “Free Radicals and Ageing” (Care Elderly 1994;6(7):260–262), was the first to address the subject in a formal mainstream UK medical journal. He was the medical columnist for the consumer periodical “Yours magazine” for a period of four years, reaching over one million readers every month. In a series of almost 700 articles, lectures, and media appearances worldwide, he discussed the subject of “Healthy Aging and Longevity” both for scientists and for the general public.
His work receives media attention nationally and internationally. He has been interviewed widely by the daily and weekly national newspapers, television, and radio in the UK on matters related to healthy aging. He has also been featured on other media in several countries.
Ashok K. Shetty, Ph.D.
Associate Director and Professor
Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine
Texas A&M Health Science Center College of Medicine, USA
Co-Editor-in-Chief: Aging and Disease
Associate Editor: Frontiers in Neurology; Frontiers in Neuroscience; Frontiers in Molecular Neuroscience; Frontiers in Aging Neuroscience
Editorial Board Member: Stem Cells; Aging Cell
Ashok K. Shetty is an Associate Director and Professor at the Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, located in College Station, Texas. Dr. Shetty has received continuous extramural research funding as Principal Investigator for over 23 years from sources such as the National Institutes of Health, Department of Defense, and Department of Veterans Affairs.
Dr. Shetty has authored 148 peer-reviewed publications (126 as Senior or First author), and his work has appeared in many top-class journals including Molecular Psychiatry, Proceedings of the National Academy of Sciences (PNAS), Neuropsychopharmacology, Journal of Neuroscience, Stem Cells, Aging Cell, Redox Biology, Progress in Neurobiology, Neuroscience and Biobehavioral Reviews, Pharmacology and Therapeutics, Brain, Behavior and Immunity, EBioMedicine, and Neurobiology of Aging. Dr. Shetty has received over 9,800 citations (with an h-index of 56) for his published research articles. Also, Dr. Shetty has the distinction of serving on two different NIH Study Sections (CNNT, DBD) as a Chartered Member. Besides, he has served as an ad-hoc member of over 50 other study section panels of different funding agencies. Dr. Shetty is a Fellow of the American Society for Neural Transplantation and Repair.
Dr. Shetty’s laboratory is interested in developing clinically applicable strategies that are efficacious for enhancing brain function after injury, disease, or aging. The central areas of investigation are focused on the following topics: (1) Mechanisms by which intranasally administered stem cell-derived extracellular vesicles (EVs) promote neuroprotection, neuroregeneration, neural plasticity, and alleviate neuroinflammation in models of penetrating traumatic brain injury (TBI), concussion or closed head injury (CHI), status epilepticus (SE), temporal lobe epilepsy (TLE), and Alzheimer’s disease (AD). (2) Mechanisms by which transplanted human neural stem cells or human GABA-ergic precursor cells derived from hiPSCs promote brain repair, and alleviate spontaneous seizures, and cognitive and mood impairments in prototypes of SE, TLE, and TBI. (3) Elucidating mechanisms of brain dysfunction and chronic neuroinflammation in prototypes of Gulf War Illness. (4) Developing clinically feasible strategies for improving hippocampal neurogenesis and memory and m